LDS/Medical Tests/Sphingomyelin Phosphodiesterase 1 (SMPD1) Mutation Analysis, Niemann-Pick Disease

Sphingomyelin Phosphodiesterase 1 (SMPD1) Mutation Analysis, Niemann-Pick Disease

Niemann-Pick disease type A and type B are autosomal recessive inherited lysosomal storage diseases and are caused by allelic mutations in the *SMPD1* gene. It is estimated that 1 in 250,000 individuals are affected by this disorder; however, the Ashkenazi Jewish and north African populations have a higher risk (the carrier rate for Ashkenazi Jews is 1 in 90 for type A). This lipid storage disorder is a result of enzyme defects in acid sphingomyelinase. The four most common mutant alleles of SMPD1 are L302P, R496L, fsP330 and deltaR608, and these are responsible for 90% of mutations. Patients with deficient enzyme activity and no or only one mutated allele should undergo full gene sequencing to detect less common mutations. Sphingomyelinase enzyme defects are characterized by accumulation of sphingomyelin in reticuloendothelial cells in addition to other cell types.

Niemann-Pick type A (infantile neurovisceral fatal form) is the more severe and progressive form due to the complete absence (<5%) of acid sphingomylenase enzyme activity. Type A is the most common form and accounts for 85% of Niemann-Pick disease SMPD1. Type A symptoms include: hepatosplenomegaly, ongoing decrease of lung function, cherry red spots of the retina, hypotonia, persistent jaundice, growth retardation, motor and developmental delays, rapid neurological degeneration, coronary artery disease and mental retardation. Type A disease is typically fatal within three years after symptom onset. Niemann-Pick disease type B (visceral form) results in a milder phenotype due to enzyme residual catalytic activity. Typical affected organs include: lungs, liver, bone marrow and spleen. Individuals diagnosed with type B typically survive into adulthood.

  • Diagnosis of Niemann-Pick disease types A or B
  • Assessment of carrier status for individuals with a family history of Niemann-Pick disease
  • Prenatal diagnosis for individuals with a known familial mutation
  • Homozygous or compound heterozygote mutations detected indicates positive result and diagnosis in an affected patient with severely deficient enzyme activity
  • Heterozygous mutation detected indicates positive result for carrier status in a person with normal enzyme activity

Negative for mutation analyzed (No mutation detected)

Exon Array CGH, Bi-directional sequencing, Polymerase chain reaction (PCR) with allele specific primer  extension (ASPE), Array comparative genomic hybridization, Conventional sequencing, Next generation sequencing (NGS).

Whole blood (EDTA or lavender top tube), buccal swab/rinse.

Prenatal screening for carrier couples with identified mutations: amniotic fluid, chorionic villi, and confluent fetal cells. A maternal blood sample must accompany all prenatal screening requests.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 7-14 days
Ashkenazi Jewish panel genetic screening, Bloom's Syndrome, Gaucher Disease, Genetic counseling, Acid sphingomyelinase enzyme activity levels (ASM) in fibroblasts, bone marrow biopsy (if indicated), Complete Blood Count (some patients have anemia and/or thrombocytopenia), Lipid profile.
5-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login